Top Markets
Coin of the day
VISEN Pharmaceuticals VISEN Pharmaceuticals

VISEN Pharmaceuticals

2561
Classificação em ações #16900
VISEN Pharmaceuticals operates as an investment holding company, concentrating... VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Preço da ação
$2.46
Valor de mercado
$268.65M
Variação (1 dia)
-1.73%
Variação (1 ano)
-57.06%
País
CN
Negociar VISEN Pharmaceuticals (2561)

Categoria

Histórico de rendimento de dividendos para VISEN Pharmaceuticals (2561)
O rendimento de dividendos (TTM) da VISEN Pharmaceuticals (símbolo da ação: 2561) em 2026 é: 0
Rendimento médio dos dividendos nos últimos 5 anos: 0.00%
Histórico de rendimento de dividendos para VISEN Pharmaceuticals (2561) de 2026 a 2026
Rendimento de dividendos no final de cada ano (TTM)
Ano Rendimento de Dividendos Alterar
Não há dados suficientes para as datas fornecidas.
Rendimentos de dividendos (TTM) para empresas semelhantes ou concorrentes